Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.57 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.53 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.51 |
| ▸ | FPR3 | P25089 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.41 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.41 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL711632 | 0.89 | MCHR1 (0.60) | MCHR1P2RX7FPR3FPR2SCN9A | |
| SCHEMBL3777504 | 0.85 | MCHR1 (0.56) | MCHR1TEAD1HTR2CSCN9ACHRM4 | |
| SCHEMBL712567 | 0.85 | MCHR1 (0.55) | MCHR1TEAD1HTR2CSCN9ACHRM4 | |
| SCHEMBL712110 | 0.81 | TEAD1 (0.46) | MCHR1P2RX7TEAD1PTPN7DUSP3 | |
| SCHEMBL712500 | 0.81 | P2RX7 (0.58) | MCHR1P2RX7FPR3FPR2SCN9A | |
| SCHEMBL708601 | 0.81 | MCHR1 (0.52) | MCHR1TEAD1SCN9ACHRM4 | |
| SCHEMBL3773431 | 0.80 | P2RX7 (0.65) | MCHR1P2RX7FPR3FPR2SCN9A | |
| SCHEMBL711001 | 0.80 | MCHR1 (0.54) | MCHR1P2RX7FPR3FPR2SCN9A | |
| SCHEMBL708521 | 0.80 | MCHR1 (0.58) | MCHR1TEAD1SCN9ACHRM4 | |
| SCHEMBL711060 | 0.77 | FPR3 (0.53) | MCHR1P2RX7FPR3FPR2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869019-B1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PROD INC (US) | 2014-08-27 | — | — | EP | claimed |
| EP-1869019-B1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PROD INC (US) | 2014-08-27 | — | — | EP | disclosed |
| US-8124639-B2 | Bicyclic [3.1.0] heteroaryl amides as type 1 glycine transport inhibitors | PFIZER INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100324020-A1 | Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors | PFIZER INC. | 2010-12-23 | — | — | US | disclosed |
| US-20060229455-A1 | Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors | PFIZER INC. | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324020-A1 | Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors | SLC1A2, SLC1A1, SLC6A5 | MCHR1 918/4885P2RX7 2105/4885TEAD1 2150/4885 |
| US-20060229455-A1 | Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors | SLC1A2, SLC1A1, GLRA1 | MCHR1 963/4885P2RX7 1885/4885TEAD1 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.